Study: NCT03894007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 iv, escalated to 100 mg/m2 if tolerated, day 1 every third week, 4 courses preoperatively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75 mg/m2 iv, escalated to 100 mg/m2 if tolerated, day 1 every third week, 4 courses preoperatively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 6 iv, day 1 every third week, 4 courses preoperatively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: AUC 6 iv, day 1 every third week, 4 courses preoperatively.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 600 mg sc, day 1 every third week, 4 courses preoperatively. 14 courses postoperatively if complete response.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: 600 mg sc, day 1 every third week, 4 courses preoperatively. 14 courses postoperatively if complete response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: 840 mg iv starting dose, thereafter 420 mg, day 1 every third week. 14 courses postoperatively if complete response in patients with baseline high risk tumours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: 840 mg iv starting dose, thereafter 420 mg, day 1 every third week. 14 courses postoperatively if complete response in patients with baseline high risk tumours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: 90 mg/m2 iv, escalated to 100 mg/m2 if tolerated, day 1 every third week, 3 courses preoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: 90 mg/m2 iv, escalated to 100 mg/m2 if tolerated, day 1 every third week, 3 courses preoperatively

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 600 mg/m2 iv, day 1 every third week, 3 courses preoperatively

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: 600 mg/m2 iv, day 1 every third week, 3 courses preoperatively

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 840 mg iv, day 1 every third week, 3 courses preoperatively if randomised to arm A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab emtansine
Description: 3.6 mg/kg iv, day 1 every third week, 14 courses postoperatively if not complete response.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab emtansine
Description: 3.6 mg/kg iv, day 1 every third week, 14 courses postoperatively if not complete response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 mg/m2 iv, day 1 weekly, 12 weeks (4 cycles), in case of (anticipated) unmanageable toxicity related to docetaxel.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 80 mg/m2 iv, day 1 weekly, 12 weeks (4 cycles), in case of (anticipated) unmanageable toxicity related to docetaxel.